| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Institute for Aging Research (N.B., G.A., J.M.B., R.B.L.), Diabetes Research and Training Center (N.B., G.A., J.M.B.), Department of Neurology (C.A.D., R.B.L.), and Department of Epidemiology and Population Health (C.A.D., R.B.L.), Albert Einstein College of Medicine, New York.
Address correspondence and reprint requests to Nir Barzilai, MD, Director: Institute for Aging Research, Belfer Bldg. #701, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461; e-mail: barzilai{at}aecom.yu.edu
Objective: To test whether cholesterol ester transfer protein (CETP) genotype (VV homozygosity for I405V) is associated with preservation of cognitive function in addition to its association with exceptional longevity.
Methods: We studied Ashkenazi Jews with exceptional longevity (n = 158; age 99.2 ± 0.3 years) for the associations of CETP VV genotype and lipoprotein phenotype, using the Mini-Mental State Examination (MMSE). To confirm the role of CETP in a younger cohort, we studied subjects from the Einstein Aging Study (EAS) for associations between CETP VV and cognitive impairment.
Results: Subjects with MMSE > 25 were twice as likely to have the CETP VV genotype (29% vs 14%, p = 0.02), and those with the VV genotype were more likely (61% vs 30%, p = 0.02) to have MMSE > 25. Subjects with the VV genotype had lower levels of CETP (1.73 ± 0.11 vs 2.12 ± 0.10 µg/mL, p = 0.01), higher high-density lipoprotein (HDL) levels (p = 0.02), and larger lipoprotein particles (p = 0.03). In the EAS cohort, an approximately fivefold increase in the VV genotype (21% vs 4%, p = 0.02), higher HDL levels, and larger lipoprotein particle sizes were associated with less dementia and improved memory.
Conclusions: Using two independent cohorts, we implicate the longevity CETP gene as a modulator of age-related cognitive function. A specific CETP genotype is associated with lower CETP levels and a favorable lipoprotein profile. It has not been determined whether modulation of this gene prevents age-related decline or AD.
This work was supported by grants from the Einstein Aging Study PO-1 (AG-021654), the Paul Beeson Physician Faculty Scholar in Aging Award, the Ellison Medical Foundation Senior Scholar Award, RO1 (AG-18728-01A1), the General Clinical Research Center (M01-RR12248), the Diabetes Research and Training Center (DK 20541) at the Albert Einstein College of Medicine, and the Baltimore VA Geriatric Research and Education Clinical Center.
Disclosure: The authors report no conflicts of interest.
Received February 2, 2006. Accepted in final form September 12, 2006.
Related articles in Neurology:
This article has been cited by other articles:
|
|
 |
|
  A. Thompson, E. Di Angelantonio, N. Sarwar, S. Erqou, D. Saleheen, R. P. F. Dullaart, B. Keavney, Z. Ye, and J. Danesh Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk JAMA, June 18, 2008; 299(23): 2777 - 2788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Perspectives on Neuroscience and Behavior Neuroscientist, August 1, 2007; 13(4): 300 - 301. [PDF]
|
|
|
|
 |
|
 From the Library Br. J. Ophthalmol., May 1, 2007; 91(5): 704 - 704. [Full Text] [PDF]
|
|
|
|
 |
|
 Genotype Predicts Phenotype: Longevity, Lipoproteins, and Cognition Journal Watch Neurology, January 23, 2007; 2007(123): 1 - 1. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
